drugset / Trial / NCT01457417
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer. To characterize the pharmacokinetic parameters of DKN-01 in cancer patients who are intolerant to standard/approved therapies.
Timeline
- Start
- 2012-01
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DKN-01 | Monoclonal antibody | 75 mg | Intravenous |
| Subject | DKN-01 | Monoclonal antibody | 150 mg | Intravenous |
| Subject | DKN-01 | Monoclonal antibody | 300 mg | Intravenous |
| Subject | DKN-01 | Monoclonal antibody | 600 mg | Intravenous |